Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first approved drug widely used for systemic therapy in advanced HCC. Sorafenib might affect polyunsaturated fatty acids (PUFA)-derived epoxygenat...

Full description

Bibliographic Details
Main Authors: Can G. Leineweber, Miriam Rabehl, Anne Pietzner, Nadine Rohwer, Michael Rothe, Maciej Pech, Bruno Sangro, Rohini Sharma, Chris Verslype, Bristi Basu, Christian Sengel, Jens Ricke, Nils Helge Schebb, Karsten-H. Weylandt, Julia Benckert
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Pharmacology
Subjects:
hepatocellular carcinoma
cytochrome P450
sorafenib
EET
EDP
omega-3 fatty acids
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1124214/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1124214/full

Similar Items